Non-interventional study on the efficiency of Erbitux in the first-line therapy in patients with metastatic colorectal cancer with wild-type KRAS gene
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Oct 2016
At a glance
- Drugs Cetuximab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms ERBITAG
- Sponsors Merck Serono
- 28 Sep 2016 According to the Merck KGaA media release, the company will present data from this trial at the ESMO 2016.
- 11 Apr 2016 New trial record
- 23 Jan 2016 Interim analysis (n=497) presented at the 2016 Gastrointestinal Cancers Symposium.